PRAN - Alterity Therapeutics Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.0000 (0.00%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.0100
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's Range1.9300 - 2.0700
52 Week Range1.0900 - 2.9100
Avg. Volume97,956
Market Cap17.284M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Business Wire13 days ago

    Alterity Therapeutics Launches to Asian Investors

    Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) (ASX: PBT, NASDAQ: ATHE) (“Alterity” or “the Company”) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow. Alterity is developing first-in-class therapies to treat neurodegenerative diseases including its lead drug candidate, PBT434 for the treatment of Parkinsonian disorders. PBT434 has received Orphan Drug designation for the first of its disease targets, Multiple System Atrophy.

  • Business Wire3 months ago

    Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

    Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Prana Biotechnology and Gilead Sciences

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / U.S. markets plunged on Thursday, with the Dow Jones falling more than 600 points, as fears of a possibility of a global economic slowdown intensified after Apple lowered revenue forecasts. The Dow Jones Industrial Average dropped 2.83 percent to close at 22,686.22, dragged mostly lower by losses in Apple’s stock, while the S&P 500 Index decreased 2.48 percent to close at 2,447.89. The Nasdaq Composite Index slumped 3.04 percent to close at 6,463.50.

  • Why Prana Biotechnology Stock Is Skyrocketing Today
    InvestorPlace4 months ago

    Why Prana Biotechnology Stock Is Skyrocketing Today

    This strategic investment from Life Biosciences will have it making an initial investment of $7.5 million into the company researching treatments for Parkinson’s disease. After this initial investment, the company will also be able to raise an additional $21.9 million from Life Biosciences and other investors. The deal will have the company issuing 272 million new fully paid ordinary shares of Prana Biotechnology stock.

  • TheStreet.com4 months ago

    Prana Biotech Surges on Promised $31.4 Million Investment

    -- a biotech company working on therapies for debilitating neurological disease -- saw its shares shoot up some up 50% to $1.92 on Wednesday, Jan. 2, after getting a promised $31.4 million investment. Boston-based Life Biosciences, a private biopharmaceutical company, is seeking the stake in Prana, and will also lend at least two new big-name board members to the Australia-based drug developer. In total, Life Biosciences could own up to 60% of Prana when the deal is completed.

  • ACCESSWIRE4 months ago

    Watch These Top Trending Stocks On Jan. 2, 2019

    CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / This past year has been wild for the stock market, but now that we're a few days into the new year, possibilities in the space are endless. As sectors across all industries try and start off the year as strong as possible, this week's investors are being presented with several stocks providing volatile upswings just after the new year. As we move, headfirst into the new year, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Prana Biotechnology Limited (NASDAQ: PRAN), Safe-T Group Ltd (NASDAQ: SFET), and vTv Therapeutics Inc (NASDAQ: VTVT) are presenting investors with potential opportunities just after the break of the new year.

  • PR Newswire4 months ago

    Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 2, 2019 /PRNewswire/ -- Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) ("Prana" or "the Company") has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC ("Life Biosciences") to raise up to approximately A$44.5 million (approx. US$31.4 million).  Life Biosciences will initially invest US$7.5 million (approx. A$10.6 million), with the agreement allowing Prana to raise an additional US$2 million from other investors, totalling US$9.5 million (approx. A$13.4 million). A further amount of up to approximately A$31 million (approx. US$21.9 million) would be invested by Life Biosciences and other investors on exercise of short-term warrants being issued as part of the transaction.

  • Simply Wall St.4 months ago

    Is Prana Biotechnology Limited’s (ASX:PBT) CEO Pay Justified?

    Geoffrey Kempler has been the CEO of Prana Biotechnology Limited (ASX:PBT) since 2005. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...

  • Simply Wall St.6 months ago

    How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)?

    Prana Biotechnology Limited (ASX:PBT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PBT Read More...

  • Business Wire7 months ago

    Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

    Prana Biotechnology Ltd (PBT.AX) (PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong on Sunday, October 7th, 2018 at 1:45pm.

  • Business Wire9 months ago

    PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical evidence for PBT434 at the International Congress of Parkinson’s Disease and Movement Disorders® to be held in Hong Kong from October 5-9, 2018. The data to be presented will include new in-vivo evidence of the efficacy of PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for PBT434.

  • Business Wire10 months ago

    First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases. The trial conducted in Melbourne, Australia is recruiting and dosing healthy adult and elderly volunteers, to ascertain the optimal drug dose.

  • Business Wire10 months ago

    Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

    Prana Biotechnology Ltd is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.